All Episodes
Making Medicine — 91 episodes
How Venture Capital Backed America's Biotech Engine | How America Makes Medicine Ep. 5
Betting on Biotech: Dr. Jeremy Levin's Playbook | How America Makes Medicine Ep. 4
The Relay Continues: Building Biotechs That Save Lives | How America Makes Medicine Ep. 3
How Research Universities Power America’s Innovation Engine | How America Makes Medicine Ep. 2
250 Years of American Pharmaceutical Innovation | How America Makes Medicine Ep. 1
FDA Leadership, China & The Future of American Biotech
Japan's Biotech Transformation: Drug Pricing, Clinical Trials & Global Investment
Maria Thacker Goethe on Biotech Growth, Clinical Trials & US Competitiveness
Why FDA Instability is Driving Biotech Capital Abroad — What Investors Are Saying
China’s Biotech Rise: What Tim Scott Saw Inside Shanghai
Patient Advocacy, FDA Partnerships & Building the Infrastructure of Drug Discovery
Healthcare Costs, PBMs & Why Manufacturers Oppose Drug Price Controls
Rep. Scott Peters on the Pill Penalty, PBMs, China & America’s Biotech Future
The FDA Decoded: Roles, Responsibilities & What They Mean for Drug Development
FDA Leadership After Marty Makary: What Biotech Needs Next
FDA Approvals Corner, Immigration Warnings & Germany's MFN Complication | Making Medicine Headlines
Senator Todd Young on China, FDA Reform, and Why Biotech Is National Security
FDA Instability Is Changing Biotech Investment—What Investors Are Saying
FDA Signals Are Breaking Biotech | Collapse, Breakthrough, and What Congress Does Next
Tariffs, MFN & FDA Delays: Why Biotech Is at Risk
The China Biotech Threat Is Already Here | John Gutierrez on Capitol Hill, Drug Pricing & FDA
Biotech, National Security, and Global Competition | Dr. Rozo (NSCEB) | JPM Re-Air
Solving Japan's Drug Lag: Why PM Takaichi Must Agree to a Fair U.S. Pricing Deal
Regulatory Risk: How FDA Instability Is Threatening America's Biotech Investment Edge
China Just Passed the U.S. in Drug Clinical Trials
Why 95% of Rare Diseases Still Have No Treatment
FDA Chaos and Foreign Price Controls Are Collapsing American Innovation
TrumpRx Explained: Cash Markets, MFN, and What This Moment Means for Drug Pricing
Speed, Scrutiny, and Spending: How Washington Is Reshaping the Future of Medicine
Live From JPM 2026: Is This the End of American Biotech Leadership?
How Global Competition and U.S. Policy Choices Are Reshaping Biotech | Live at JPM 2026 (Part 2)
Innovation at a Crossroads | Live at JPM 2026 (Part 1)
CMS Drug Pricing Proposals and What JPM 2026 Signals
How Policy Shapes the Future of Life Sciences
Year in Review: Biotech Innovation, Policy, and Global Competition
Biotech in 2025: Investment Trends, Congress, and Approvals
What the NDAA Means for the Future of Biotech
Inside Congress: Senator Thom Tillis on Drug Pricing, IP, and the Future of Innovation
Making Medicine ft. Daphne Zohar. Biotech Flywheels, Policy Risks, and the Future of Innovation
Japan’s Life Sciences State of Play: The Takeaways You Can’t Miss
Inside Biotech Leadership: Bill Newell on Innovation, Capital, and Policy at Sutro Biopharma
U.S. Biomanufacturing Surge, Arena BioWorks Fallout & GLP-1 Rumors | Making Medicine Podcast
Is the U.S. Losing Its Biotech Edge to China? Senate Hearing & Innovation Outlook
FDA Vouchers, Orphan Cures & IP with Joshua Kresh
Shutdown Fallout, MFN Deals & BIOSECURE Returns
Boston Biotech Pulse: Shutdowns, Pfizer Deal, and the Future of Innovation
Government Shutdown, SBIR Expiration, and Trump’s Pharma Moves | Making Medicine Podcast
China’s Biotech Surge, GLP-1 Prices, & MFN Deadline | Press Pass with Max Bayer
UK Pharma Challenges, DTC Ads Debate & 5 New FDA Approvals | Making Medicine
Ending the Pill Penalty on 9/13, Tariffs & FDA Rare Disease Guidance | Making Medicine
MassBio’s 2025 Snapshot: VC Gravity, Policy & a Competitiveness Playbook | Kendalle Burlin O’Connell
Trump’s Tariffs, NIH Cuts, FDA Approvals & SBIR Debate | This Week in Making Medicine
Ned Sharpless on Biotech’s Future, HHS Shifts, and Global Competition | Making Medicine Podcast
FDA Shake-Ups & mRNA Funding Cuts | Industry Perspectives with Patrick Jordan
President Trump’s “Most Favored Nation” Drug Pricing Plan: Good Deal or Dangerous Gamble?
Listener Q&A: Drug Price Controls, EU Tariffs, and the August Recess | Making Medicine Podcast
Unpacking Uncertainty: Trump’s Health Policies & Future of FDA | Press Pass with Nyah Phengsitthy
Trump’s 200% Pharma Tariff? Timeline, Impacts, and What Comes Next | Making Medicine Podcast
Big Beautiful Bill Breakdown, Orphan Cures Win, and What’s Next | Making Medicine Podcast Relaunch
When Progress Gets Penalized: Biotech in the Age of IRA
Bridging Science and Business: A Conversation with Professor Fred Ledley
Can We Fix Healthcare? A Look Inside Our System
Protecting Innovation: Small Molecules and the Future of Medicine
CEO Series Part 1: Sherine Chan, CEO & Co-founder of Neuroene Therapeutics
Dispelling Misconceptions in Biopharmaceutical IP Regulation
When the Feds Come Marching In: A Deep Dive on The Bayh-Dole Act
Beyond Medicine: Solving Disparities in Cancer Care
Balancing Access and Affordability in the Future of Healthcare
Making Patients the Center of U.S. Healthcare Reform
Innovations in Women’s Health & Entrepreneurship
The Inflation Reduction Act: A Big Issue for Small-Molecule Medicine
From the JP Morgan Conference: The Impact of the Inflation Reduction Act
Drug Investment Under the Inflation Reduction Act
The Three Pillars of Bio & Med Tech Investing and Industry Impact of DEI
Understanding Health Equity w/ Dr. Jerome Adams
Addressing The Overlooked AMR Problem w/ Dr. Henry Skinner
Pro-Patient Reforms: The Outlook for 2022
How Better Data Fosters Health Equity w/ Kirsten Axelsen
Winning the Drug Development Relay Race w/ Johannes Fruehauf
New Modalities: The Future of Drug Development w/ Jean-Francois Formela
The Investor’s Paradox, Drug Development, & Price Controls w/ Peter Kolchinsky
MIT Takeover: A MedTech-VC Partnership Working to Reduce Parkinson’s Tremors
Venture Capital Investors: The Underwriters of Innovation w/ Janis Naeve, Brian Bradbury, and Alan Brookhart
The Hidden Cost of Price Control Policies w/ Kirsten Axelsen
You Cannot Make Medicine Alone: Relationships & Mentoring w/ Imran Nasrullah
Improving the Standard of Care w/ Patients in Mind
The Truth About Pharmaceuticals w/ Ravi Mehrotra
Valuing Inventors & Entrepreneurs: Changing the Dialogue of IP w/ Andrei Iancu
AMR: Challenges and Insight w/ Alfonso Chang
40 Years in Review: Bayh-Dole to 2021 w/ Joe Allen
Making Medicine: An Origin Story